Khan Z, Ghafoor D, Khan A, Ualiyeva D, Khan S A, Bilal H, Khan B, Khan A, Sajjad W
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
University of Chinese Academy of Sciences, Beijing, China.
New Microbes New Infect. 2020 Nov;38:100770. doi: 10.1016/j.nmni.2020.100770. Epub 2020 Sep 30.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city of China in late December 2019 and identified as a novel coronavirus. Due to its contagious nature, the virus spreads rapidly and causes coronavirus disease 2019 (COVID-19). The global tally of COVID-19 was 28 million in early September 2020. The fears and stress associated with SARS-CoV-2 has demolished the socio-economic status worldwide. Researchers are trying to identify treatments, especially antiviral drugs and/or vaccines, that could potentially control the viral spread and manage the ongoing unprecedented global crisis. To date, more than 300 clinical trials have been conducted on various antiviral drugs, and immunomodulators are being evaluated at various stages of COVID-19. This review aims to collect and summarize a list of drugs used to treat COVID-19, including dexamethasone, chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, remdesivir, tociluzimab, nitazoxanide and ivermectin. However, some of these drugs are not effective and their use has been suspended by WHO.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）于2019年12月底在中国武汉市出现，并被确定为一种新型冠状病毒。由于其传染性，该病毒迅速传播，导致了2019冠状病毒病（COVID-19）。2020年9月初，全球COVID-19病例总数达到2800万。与SARS-CoV-2相关的恐惧和压力摧毁了全球的社会经济状况。研究人员正在努力寻找治疗方法，特别是抗病毒药物和/或疫苗，以控制病毒传播并应对这场前所未有的全球危机。迄今为止，已经针对各种抗病毒药物进行了300多项临床试验，并且在COVID-19的各个阶段正在对免疫调节剂进行评估。本综述旨在收集并总结用于治疗COVID-19的药物清单，包括地塞米松、氯喹、羟氯喹、洛匹那韦/利托那韦、法匹拉韦、瑞德西韦、托珠单抗、硝唑尼特和伊维菌素。然而，其中一些药物并无效果，世界卫生组织已暂停其使用。
